RESUMO
Our objectives were to determine the etiology and analyze the antibiotic resistance profiles of microorganisms causing uncomplicated urinary tract infections in our setting. An analytical cross-sectional study was conducted. In vitro antimicrobial resistance of urine cultures was analyzed. 580 urine cultures of women over age fifteen were included. 82.6 % of urine cultures corresponded to cystitis and the remaining 17.4 % corresponded to pyelonephritis. 353 urine cultures of women <50 years old (60.9%) and 227 of women = 50 years old (39.1%) were obtained. The most common pathogens were Escherichia coli (85.5 %) and Klebsiella pneumoniae (4.7 %). For Escherichia coli, there was a resistance of 28.6% to trimethoprim-sulfamethoxazole,7.9% to ciprofloxacin and 0.4% to nitrofurantoin. Significant difference (p = 0.005) was seen in the resistance to ciprofloxacin in women = 50 years old. Our data show there is a low in vitro resistance to nitrofurantoin
Nuestros objetivos fueron determinar la etiología y analizar los perfiles de resistencia antimicrobiana de los microorganismos causantes de infecciones urinarias no complicadas en nuestro medio. Se realizó un estudio analítico de corte transversal. Se analizó la resistencia antimicrobiana in vitro de los urocultivos. Se incluyeron 580 urocultivos de mujeres mayores de 15 años. Un 82.6% de urocultivos correspondieron a cistitis y el 17.4% a pielonefritis.Se obtuvieron 353 urocultivos de mujeres < 50 años (60.9%) y 227 a ? 50 años (39.1%).Los patógenos más frecuentes fueron: Escherichia coli (85.5%) y Klebsiella pneumoniae (4.7%). Se encontró una resistencia de E coli a trimetoprima-sulfametoxazol del 28.6%, a ciprofloxacina de 7.9% y a nitrofurantoína de 0.4%. Se evidenció diferencia significativa (p=0.005) en la resistencia de E coli a ciprofloxacina en las mujeres ?50 años de edad. Nuestros datos muestran que existe una baja resistencia in vitro a nitrofurantoína.
Assuntos
Antibacterianos/farmacologia , Cistite/microbiologia , Farmacorresistência Bacteriana Múltipla , Bactérias Gram-Negativas/efeitos dos fármacos , Bactérias Gram-Positivas/efeitos dos fármacos , Pielonefrite/microbiologia , Adolescente , Adulto , Fatores Etários , Idoso , Estudos Transversais , Cistite/tratamento farmacológico , Feminino , Bactérias Gram-Negativas/classificação , Bactérias Gram-Positivas/classificação , Humanos , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Pielonefrite/tratamento farmacológicoRESUMO
BACKGROUND: There are few data in Argentina on the prevalence and management of bone and mineral metabolism (BMM) in patients with chronic kidney disease (CKD). OBJECTIVES AND METHODS: A survey was carried out in dialysis units in 2010 to measure the prevalence of and types of treatments for BMM disorders in Argentina. The data obtained was then compared to the published results from other large population studies. We recorded characteristics of dialysis centres and participating patients, the frequency of measurements and individual results for BMM biochemical markers, as well as the type of management used to control hyperphosphataemia and secondary hyperparathyroidism. RESULTS: 1210 patients from 25 dialysis centres in Argentina participated in the study (representing 4.7% of the country's prevalent dialysis population in 2010). The mean patient age was 55.3±17.6 years, 60.8% were male, 3.3% were on peritoneal dialysis and 29.1% suffered diabetes. In all centres, phosphataemia and calcaemia were measured on a monthly basis, 60% of centres measured intact parathyroid hormone (iPTH) every 6 months, 36% every 3 to 4 months, and 4% annually. As recommended by K/DOQI, 51.6% of patients had adequate levels of calcium (8.4-9.5 mg/dl), 51.6% had adequate phosphorus (3.5-5.5 mg/dl) and 21.1% displayed acceptable iPTH levels (150-300 pg/ml). 24% had iPTH <150 pg/ml and 54.5% >300 pg/ml. iPTH ≥600 pg/ml was present in 28.3%, and 13.3% had values ≥1000 pg/ml. These figures differed from those published by the DOPPS II study, in which 51.1% of patients had iPTH <150 pg/ml, and only 26.7% had iPTH ≥300 pg/ml. Calcium-based phosphate binders were used in 83.6% of the patients, 5.6% used sevelamer and 4.0% used aluminium-containing compounds. To achieve control of hyperparathyroidism, oral or intravenous calcitriol was predominantly used (50.5%) with a small percentage of patients receiving paricalcitol or doxercalciferol. CONCLUSIONS: The present study shows a high prevalence of secondary hyperparathyroidism, which differs from that published by other large population studies. There was a high proportion of patients with BMM markers outside the ranges suggested by K/DOQI. Mainly phosphate binders based on calcium and calcitriol continue to be used for the management of hyperphosphatemia and hyperparathyroidism respectively.